Group 1 - Major shareholder Guo Lei and his concerted parties planned to reduce their holdings from July 17 to October 14, 2025, by no more than 16,327,928 shares, accounting for 2.68% of the total share capital [1] - As of September 28, 2023, a total of 16,027,928 shares have been reduced, ending the reduction plan ahead of schedule [1] - The reduction included 5.45 million shares sold by Guo Lei at an average price of 10.01 yuan per share, and various transactions by two funds, resulting in a combined holding percentage dropping from 7.6658% to 5.0151% [1] Group 2 - The two funds, A Xing Yan An No. 20 and A Xing Yan An No. 22, have completely divested their holdings, leading to the automatic termination of the concerted action relationship with Guo Lei [1] - The reduction complies with regulations and does not affect the company's control [1]
迈克生物:持股5%以上股东减持计划提前结束并解除一致行动关系